

16th August, 2021

To,
The Manager,
Dept. of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001
Scrip Code: 511509

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Advertisement in Newspaper

With reference to the subject cited above we are herewith enclosing the copies of advertisement issued in newspapers on 15th August, 2021 in “**Financial Express**” in English Language and in “**Nava Telangana**” in Telugu Language, with respect to publication of Un-Audited Consolidated Financial Results for the First quarter ended 30th June, 2021.

This is for your information and records.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

A. Karthik

A. Karthik
Company Secretary



VIVO BIO TECH LIMITED

Your Drug Discovery Partner
CIN: L65993TG1987PLC007163

8-2-672/ 5 & 6, 3rd Floor, Ilyas Mohammed Khan Estate, Road No. 1, Banjara Hills, Hyderabad - 500034, Telangana, India. Ph. No.: 040 - 2331 3288 E-mail: investors@vivobio.com / Website: www.vivobio.com

EXTRACT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021

(Rs. in Lacs except per equity share data)

Sl. No.	Particulars	QTR ENDED	QTR ENDED	QTR ENDED	YEAR ENDED
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		Un-Audited	See Note#2 below	Un-Audited	Audited
1	Total Income from Operations	1321.78	1615.99	915.40	5185.38
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	219.06	107.60	91.84	861.97
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	219.06	107.60	91.84	861.97
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	123.94	29.75	97.76	568.23
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	123.94	29.75	97.76	568.23
6	Equity Share Capital	1420.45	1341.95	1288.75	1341.95
7	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)				
	i. Basic	0.87	0.22	0.76	4.23
	ii. Diluted	0.84	0.22	0.76	4.19

Notes:
1. The above Un-Audited Financial Results are reviewed and recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 13th August, 2021.
2. The figures for the quarter ended 31st March 2021 are the balancing figures between the audited figures of the full financial year ended 31st March 2021 and the published year-to-date figures upto the 3rd quarter of respective financial years which were subject to Limited Review by the Statutory Auditor of the Company.
3. The above Consolidated Results include results of all Subsidiaries.
4. The above is an Extract of the detailed format of Quarterly Un-Audited Financial Results filed with stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the stock exchange website www.bseindia.com and company's website www.vivobio.com.
5. Standalone Financial Information of the Company are as under:

Particulars	QUARTER ENDED	QUARTER ENDED	QUARTER ENDED	YEAR ENDED
	30.06.2021	31.03.2021	30.06.2020	31.03.2021
		Un-Audited	See Note#2 above	Audited
Total Income	1,321.16	1,615.99	915.40	5,185.38
Profit before Tax	218.44	107.79	91.84	862.18
Profit for the Period	123.32	29.95	97.76	568.44

For Vivo Bio Tech Limited

Sd/-
M. Kalyan Ram
Whole Time Director
DIN: 02012560

Date: 13th August, 2021
Place: Hyderabad

SHREE RAMA NEWSPRINT LIMITED

Registered Office : Village : Barbothan, Taluka : Olpad, Dist. Surat, Pin-395 005 (Gujarat)
Tel: 02621-224203, 224204, 224205, 224207
E-mail: ramanevnewsprint@ramanevnewsprint.com • CIN : L21010G1991PLC019432

(Rs. in lakhs)

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended
		30.06.2021	31.03.2021	30.06.2020
1	Total Income from Operations	10,598.65	14,156.15	4,476.93
2	Net Profit / (Loss) for the period (before tax and exceptional items)	(1,371.31)	160.40	(2,076.95)
3	Net Profit / (Loss) for the period before tax (after exceptional items)	(1,371.31)	160.40	(2,076.95)
4	Net Profit / (Loss) for the period after tax (after Exceptional items)	(1,371.31)	160.40	(2,076.95)
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	(1,368.99)	187.14	(2,083.04)
6	Equity Share Capital	14,752.20	14,752.20	14,752.20
7	Other Equity	-	-	-
8	Earnings Per Share (of ₹ 10/- each) (not annualised)			
	Basic (in ₹)	(0.93)	0.11	(1.41)
	Diluted (in ₹)	(0.93)	0.11	(1.41)

NOTES:
1. The above financial results for the quarter ended June 2021 were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on August 14, 2021
2. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Results are available on the websites of the Stock Exchange(s) www.bseindia.com & www.nseindia.com and on company's website www.ramanevnewsprint.com
For Shree Rama Newsprint Limited

Place : Ahmedabad
Date : 14.08.2021

Siddharth Chowdhary
Executive Director
DIN: 01798350

MORGAN VENTURES LIMITED

CIN:L70109DL1986PLC025841
Regd. Office: 37, Ring Road, Lajpat Nagar – IV, New Delhi 110024
EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021
(Financial Results (Amount in Rs. Lakhs))

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		(UnAudited)	(Audited)	(UnAudited)	(Audited)
1.	Total Income from Operations	122.42	106.88	184.88	580.98
2.	Total Expenses	59.35	57.82	92.87	292.74
3.	Net Profit for the period (before exceptional items)	63.07	49.06	92.01	288.24
4.	Net Profit for the period before tax	63.07	49.06	92.01	288.24
5.	Net Profit for the period after tax	63.07	93.61	92.01	145.57
6.	Total Comprehensive income for the period	0	0	0	0
7.	Paid Up equity share capital (Face Value Rs. 10/-)	994.93	994.93	994.93	994.93
8.	Basic and Diluted Earnings Per Share (EPS)	0.63	-0.93	0.92	1.47

Notes:
1. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchanges websites (www.bseindia.com) and Companies website (www.morganventures.in)
2. The above results have been unaudited by the Statutory Auditors of the Company, reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th August, 2021.
Place: New Delhi
Date: August 14, 2021
For Morgan Ventures Limited
Sd/-
Kuldeep Kumar Dhar (Managing Director)



HINDCON CHEMICALS LIMITED

CIN :- L24117WB1998PLC087800
Registered Office :- 62B, Braunfeld Row, 1st Floor, Kolkata - 700 027
Email id :- contactus@hindcon.com , Website :- www.hindcon.com

EXTRACT OF THE UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021

Sl. No.	Particulars	Standalone Results			Consolidated Results		
		Quarter ended	Quarter ended	Previous Year	Quarter ended	Quarter ended	Previous Year
		on 30/06/2021	on 30/06/2020	31/03/2021	on 30/06/2021	on 30/06/2020	31/03/2021
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations (net)	1,351.09	798.94	4,629.04	1,371.52	801.24	4,642.19
2	Net Profit for the period (Before Tax and Exceptional items)	164.26	147.97	635.21	166.80	149.81	644.98
3	Net Profit/(Losses) for the period before tax (After Exceptional items)	164.26	147.97	635.21	166.80	149.81	644.98
4	Total Comprehensive Income for the period (Comprising Profit for the period after tax and Other Comprehensive Income after Tax)	170.62	134.74	564.28	191.32	148.64	603.24
5	Paid up Equity Share Capital (Face Value ₹10/- each)	1,023.81	1,023.81	1,023.81	767.20	767.20	767.20
6	Basic & Diluted Earnings Per Share (Face Value ₹ 10/- each) (not Annualised)	1.20	1.09	4.64	1.62	1.47	6.22

Notes:
1. The Board has declared interim dividend @10% (i.e. Re.1/= per share) on the paid up value of ₹ 10/= each for the FY 2021-22 and the same will be paid within stipulated time.
2. The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the National Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the company's Website - (https://www.hindcon.com) and National Stock Exchange website - (www.nseindia.com).
3. The previous period figures have been regrouped/rearranged wherever necessary, to confirm to the current period figures.
4. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) as notified under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended. The Company has migrated from SME Board to Main Board of NSE from July 5, 2021 and therefore adopted Ind AS during the year with the transition date as 1st April, 2020. Financial results for all the periods presented above have been prepared in accordance with the recognition and measurement principles of Ind AS 34 - Interim Financial Results.

For and on behalf of the Board
Hindcon Chemicals Limited
Sd/-
Sanjay Goenka
Chairman & Managing Director
DIN - 00848190

Place : Kolkata
Date : August 14, 2021



AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE: New No.103 (Old No.42-45), Luz Church Road, Mylapore, Chennai-600 004
email id: investors@amrutanjan.com | website: www.amrutanjan.com | CIN No: L24231TN1936PLC000017



EXTRACT FROM THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021



(Rs. In lakhs other than EPS)

Particulars	Quarter ended			Year ended
	30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
	(Unaudited)	(Audited - Ref Note -4)	(Unaudited)	(Audited)
Total Income from Operations	7,821.15	9,401.68	4,661.85	33,284.40
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1,628.62	1,371.15	866.12	8,190.45
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	1,628.62	1,371.15	866.12	8,190.45
Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	1,205.74	1,022.88	642.72	6,119.04
Total Comprehensive Income for the period (comprising Profit / (loss) for the period (after tax) and Other comprehensive Income (after tax))	1,203.15	1,027.56	639.85	6,116.24
Equity Share Capital	292.31	292.31	292.31	292.31
Reserves (excluding Revaluation Reserve)	21,264.16 (As on 31-03-2021)	21,264.16 (As on 31-03-2021)	15,650.25 (As on 31-03-2020)	21,264.16 (As on 31-03-2021)
Earnings Per Share (Re.1/- each)				
Basic	4.12	3.50	2.20	20.94
Diluted	4.12 (not annualised)	3.50 (not annualised)	2.20 (not annualised)	20.93 (annualised)

Note :
1. The above is an extract of the detailed format of Quarterly and year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and year ended Financial Results are available on the Stock Exchange websites www.bseindia.com and www.nseindia.com and on the Company's website www.amrutanjan.com.
2. The above financial results for the quarter ended 30 June 2021 in respect of Amrutanjan Health Care Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 14 August 2021. The above results have been subjected to limited review by the statutory auditor of the Company. The report of the statutory auditors is unqualified.
3. These financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. The figures for the quarter ended 31 March 2021 are the balancing figures between audited figures in respect of previous full financial year and published unaudited year to date figures up to the end of the third quarter of the relevant financial year, which were subjected to limited review and not subjected to audit.

Place: Chennai
Date : 14th August 2021

For Amrutanjan Health Care Limited
-s/d
S. Sambhu Prasad
Chairman & Managing Director

IFGL REFRACTORIES LIMITED

CIN : L51909OR2007PLC027954
Registered Office : Sector B, Kalunga Industrial Estate, P.O. Kalunga-770031, Dist: Sundergarh, Odisha
Head & Corporate Office : McLeod House, 3, Netaji Subhas Road, Kolkata-700001
E-mail : ifgl.ho@ifgl.in, Website : www.ifglref.com

EXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021

Particulars	Quarter ended			Year ended
	30.06.2021	31.03.2021	30.06.2020	31.03.2021
	Unaudited	Audited	Unaudited	Audited
		Refer Note 4		
Total Income	27,784	28,794	20,637	1,04,245
Net Profit before Tax from Ordinary Activities	2,305	3,522	1,385	12,422
Net Profit / (Loss) after Tax and exceptional item	1,787	(253)	1,019	6,559
Total Comprehensive Income / (Loss) (Comprising Profit / (Loss) for the period after Tax and Other Comprehensive Income after Tax)	2,598	(45)	1,138	8,154
Paid up Equity Share Capital (Face Value ₹ 10/- per Share)	3,604	3,604	3,604	3,604
Other Equity	-	-	-	85,445
Earnings Per Share (of ₹ 10/- each) Basic and Diluted #	4.96	(0.70)	2.83	18.20
Earnings Per Share (of ₹ 10/- each) Basic and Diluted # (Adjusted) (refer note 2)	4.96	5.30	2.83	23.80

Figures for the quarter are not annualised.
NOTE:
1. Above financial results have been reviewed by the Audit Committee at its meeting held on 14 August, 2021 and approved by the Board of Directors (Board) at their meeting held on that date. The Statutory Auditor has reviewed the same.
2. Following amendments made by the Finance Act, 2021 to the relevant sections of the Income Tax Act 1961, whereby Goodwill on amalgamation will not be considered as a depreciable asset and depreciation on goodwill will not be allowed as deductible expenditure effective 1st April, 2021, the Holding Company, in accordance with the requirements of Ind-AS 12, had recognised one time deferred tax charge of ₹ 2,165 lakhs for the quarter ending 31st March, 2021 (including adjustment for corresponding net deferred tax credit recognised in prior quarters) and ₹ 2,019 lakhs (net) for the year ended 31st March, 2021 consequent to the reduction of the depreciable amount of goodwill for tax purposes to nil. Accordingly, profit after tax for the quarter ended 31st March, 2021 and year ended 31st March, 2021 are lower by respective amounts as indicated above. This deferred tax charge does not involve any cash outflow either in the current year or future. Adjusted EPS for the quarter ended 31st March, 2021 and year ended 31st March, 2021 had been calculated without taking into consideration such additional deferred tax charge. Deferred tax liability of ₹ 158 lakhs on goodwill amortised during the quarter has been credited against tax expense for the quarter ended June'21.
3. Key Stand-alone financial information are as follows:

Particulars	Quarter ended			Year ended
	30.06.2021	31.03.2021	30.06.2020	31.03.2021
	Unaudited	Audited	Unaudited	Audited
		Refer Note 4		
Total Income	16,315	17,675	12,988	65,584
Net Profit before Tax from Ordinary Activities	1,754	2,648	1,602	10,130
Net Profit / (Loss) after Tax from Ordinary Activities	1,339	(1,091)	1,194	4,484
Total Comprehensive Income / (Loss) (Comprising Profit / (Loss) for the period after Tax and Other Comprehensive Income after Tax)	1,346	(1,061)	1,193	4,511

4. The figures of the last quarter ended 31st March, 2021 are the balancing figures between the audited figures in respect of the financial year ended 31st March, 2021 and the unaudited published year to date figures up to 31st December, 2020, being the date of the end of the third quarter of that financial year, which was subjected to limited review.
5. This is an extract of the detailed format of unaudited Consolidated and Stand-alone Financial Results for the quarter ended 30th June, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Detailed format of the unaudited Consolidated and Stand-alone Financial Results are available on the Websites of BSE (www.bseindia.com), NSE (www.nseindia.com) and Company's Website (www.ifglref.com).

On behalf of the Board
of IFGL Refractories Limited
S K Bajoria
Chairman
(DIN: 00084004)

Kolkata
14th August, 2021



అందరి చూపు..దళిత బంధు వై.. పూజారాబాద్ వేదికగా 16న ప్రారంభించనున్న సీఎం



సవతెలంగాణ - కరీంనగర్ ప్రాంతీయ ప్రతినిధి నేల రోజులుగా హాట్ టాపిక్ గా మారిన 'దళిత బంధు' పథకంపై రాష్ట్రంలో అందరూ చూస్తున్నారు. ఈ నెల 16న పూజారాబాద్ వేదికగా సీఎం కేసీఆర్ ప్రారంభించనున్న ఈ స్కీం మార్గదర్శకాలపై ఉత్తరం నెలకొంది. స్కీం అమలులో వచ్చే ప్రతిబంధకాలను తొలగించేందుకు ఈ పైలట్ ప్రాజెక్టు అంటున్న సర్కారు సమగ్ర కుటుంబ సర్వే డేటా ఆధారంగానే అర్హులను గుర్తిస్తామంటోంది. కరీంనగర్ ఉమ్మడి జిల్లా మంత్రులు సహా జిల్లా యంత్రాంగమంతా పూజారాబాద్ లోనే మకాం వేయగా.. శనివారం రాష్ట్ర ప్రభుత్వ ప్రధాన కార్యదర్శి సోమేశ్ కుమార్ పర్యటించారు. దళితబంధు విధివిధానాలు చెబుతూ అధికారులతో సీఎం సభ ఏర్పాటుపై సన్నాహక సమీక్షలు నిర్వహించారు. జాబితాలో పేరు రాబోయే పలు గ్రామాల్లో రెండ్రోజులుగా ఆందోళనలు చేస్తుంటామంటే అలసత్వమైనా అర్హులందరికీ అందిస్తామని ప్రభుత్వం చెబుతోంది. మరోవైపు సీఎం సభకు జనసమీకరణ బాధ్యత ప్రభుత్వ ఉపాధ్యాయులకు అప్పగించడంపై సర్కూర్లు విమర్శలు తావిచ్చింది.

- సమగ్ర కుటుంబ సర్వే ఆధారంగా అర్హులను ఎంపిక
107 గ్రామాల్లో సర్వేకు బృందాలు సిద్ధం
జాబితాలో చోటులేదని తదలితుల ఆందోళన
అలసత్వమైనా అందరికీ అర్హులను అందిస్తామని ప్రభుత్వం చెబుతోంది
సీఎం సభ జనసమీకరణకు పంతుళ్లకు బాధ్యతలపై విమర్శలు

Table for VIVO BIO TECH LIMITED. Includes company details (CIN: L65993TG1987PLC007163), financial statements for FY 2021, and a list of directors. The table shows financial metrics like revenue, expenses, and profit for various quarters.

Table for BRIGHTCOM GROUP LIMITED. Includes company details (CIN: L64203TG1999PLC030996), financial statements for FY 2021, and a list of directors. The table shows financial metrics like revenue, expenses, and profit for various quarters.

Table for ఆబ్జెక్ట్ వన్ ఇన్ఫర్మేషన్ సిస్టమ్స్ లిమిటెడ్. Includes company details (CIN: L31300TG1996PLC023119), financial statements for FY 2021, and a list of directors. The table shows financial metrics like revenue, expenses, and profit for various quarters.

Table for TAAZA INTERNATIONAL LIMITED. Includes company details (CIN: L72200TG2003PLC041860), financial statements for FY 2021, and a list of directors. The table shows financial metrics like revenue, expenses, and profit for various quarters.

Table for GSS Infotech Limited. Includes company details (CIN: L72200TG2003PLC041860), financial statements for FY 2021, and a list of directors. The table shows financial metrics like revenue, expenses, and profit for various quarters.

Table for PALRED TECHNOLOGIES LIMITED. Includes company details (CIN: L72200TG1999PLC033131), financial statements for FY 2021, and a list of directors. The table shows financial metrics like revenue, expenses, and profit for various quarters.

Table for GSS Infotech Limited (continued). Includes financial statements for FY 2021, and a list of directors. The table shows financial metrics like revenue, expenses, and profit for various quarters.